Serenity Bioworks Acquires DC-TAB for Lupus Nephritis
Serenity Bioworks announces it has completed the acquisition of DC-TAB, a recombinant human HspB5 that was previously in clinical development for relapse-remitting multiple sclerosis.…
Read More...
Read More...
